Last reviewed · How we verify
Active Psoriatic Arthritis with Distal Interphalangeal Involvement — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| TNF Inhibitor | tnf-inhibitor | Pfizer | Monoclonal Antibody | TNF-alpha |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Active Psoriatic Arthritis with Distal Interphalangeal Involvement
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Active Psoriatic Arthritis with Distal Interphalangeal Involvement:
- Active Psoriatic Arthritis with Distal Interphalangeal Involvement treatment updates — RSS
- Active Psoriatic Arthritis with Distal Interphalangeal Involvement treatment updates — Atom
- Active Psoriatic Arthritis with Distal Interphalangeal Involvement treatment updates — JSON
Cite this brief
Drug Landscape (2026). Active Psoriatic Arthritis with Distal Interphalangeal Involvement — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/active-psoriatic-arthritis-with-distal-interphalangeal-involvement. Accessed 2026-06-10.
Related
- Active Psoriatic Arthritis with Distal Interphalangeal Involvement full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing